# US 2005/0232907 A1 · Use of herpes vectors for tumor therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232907 A1
- Document ID: US20050232907A1
- Status: Published application
- Kind: A1
- Application number: 11/097,391
- Filed: 2005-04-04
- Published: 2005-10-20
- Earliest claimed: 1997-08-12
- Assignees: Georgetown University
- Inventors: Samuel Rabkin; Masahiro Toda; Robert Martuza
- Web page: https://patentgrep.com/patent/US20050232907A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 35/763: Herpes virus
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/208: {IL-12}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- C12N 15/86: Viral vectors
- A01K 2267/0331: Animal model for proliferative diseases
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N 2800/108: episomal vectors
- C12N 2840/203: having an IRES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator. In another embodiment, the pharmaceutical composition comprises, in addition to a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells, a viral vector comprising at least one expressible nucleotide sequence coding for at least one immune modulator.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells, with a genome comprising (i) at least one expressible nucleotide sequence encoding at least one immune modulator and (ii) a mutation in the γ34.5 gene.

### Claim 36 (depends on 35)

The HSV of claim 35, wherein both copies of said γ34.5 gene are mutated.

### Claim 37 (depends on 35)

The HSV of claim 35, wherein said HSV further comprising at least one further gene mutation.

### Claim 38 (depends on 35)

The HSV of claim 35, wherein said at least one further gene mutation is in ribonucleotide reductase.

### Claim 39 (depends on 35)

The HSV of claim 35, wherein said HSV is G207.

### Claim 40 (depends on 35)

The HSV of claim 35, wherein said immune modulator is selected from the group consisting of a cytokine, a co-stimulatory molecule and a chemokine.

### Claim 41 (depends on 35)

The HSV of claim 35, wherein said immune modulator is selected from the group consisting of IL-1, L-2, IL-3, IL-4, IL-6, IL-7, IL-12, G-CSF, GM-CSF, IFN-α, IFN-γ, TNF-α and B7

### Claim 42 (depends on 35)

The HSV of claim 35, wherein said immune modulator is selected from the group consisting of GM-CSF and IL-12.

### Claim 43 (depends on 35)

The HSV of claim 35, wherein the tumor cells are of a type selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, and medulloblastoma.

### Claim 44 (depends on 35)

A composition comprising the HSV of claim 35 and a pharmaceutically acceptable vehicle for said HSV.
